New York-based healthcare funding agency OrbiMed has invested a complete of $85 million in Swiss firm vVARDIS, identified for its drill-free therapy for early tooth decay, the businesses mentioned in a current assertion.
OrbiMed introduced the closing of a $50 million funding spherical, including to an preliminary $35 million funding made in February 2025.
“After our preliminary funding, we’ve seen firsthand the momentum vVARDIS is constructing within the dental market with its Curodont™ merchandise,” mentioned Matthew Rizzo, common associate at OrbiMed. He added that Curodont is “gaining actual traction.”
Provided in 10% of U.S. dental clinics
Drs. Haley and Goly Abivardi, founders and co-CEOs of vVARDIS, mentioned Curodont is now provided in practically 10 per cent of U.S. dental workplaces.
Moreover, a couple of million enamel have been handled with Curodont in the USA since January 2024, and over 400,000 sufferers have acquired therapy thus far this 12 months, in line with their press launch.
“That’s why we’re excited to deepen our dedication and broaden our funding to assist vVARDIS in its subsequent part of progress,” Rizzo mentioned.
FDA-approved since 2019
Curodont acquired CE marking approval to be used within the European Union and Switzerland in 2012. It entered varied worldwide markets beginning in 2016 and acquired U.S. Meals and Drug Administration clearance in 2019, permitting its industrial availability in the USA.
Younger Improvements, producer and distributor of dental provides and tools, primarily based in Algonquin, Illinois., started distributing Curodont Restore Fluoride Plus in 2021.
In September 2024, Henry Schein introduced it’s now the unique distributor within the U.S. for Curodont Restore Fluoride Plus, a non-invasive preventive therapy for early-stage cavities.
Learn associated article: Henry Schein turns into unique U.S. distributor for non-Invasive cavity therapy Curodont
